Literature DB >> 15608317

Lupus erythematosus with leflunomide: induction or reactivation?

D Gensburger1, M Kawashima, H Marotte, J Kanitakis, P Miossec.   

Abstract

BACKGROUND: Leflunomide is a new oral disease modifying antirheumatic drug with a good safety profile. CASE REPORT: The first case of lupus erythematosus in a 58 year old white woman after administration of leflunomide for primary Sjögren's syndrome is reported. The relationship between induced lupus and leflunomide was confirmed by the resolution of the skin rash when the drug was stopped and its recurrence when it was reintroduced following a dose-response effect. DISCUSSION: Peripheral blood cells from this patient, from 15 patients with rheumatoid arthritis, and from healthy controls were used in a bioassay, which suggested that leflunomide affected the Th1/Th2 balance. Such a side effect might be related, in part, to the anti-tumour necrosis factor alpha activity of leflunomide.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15608317      PMCID: PMC1755207          DOI: 10.1136/ard.2003.019323

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  5 in total

1.  Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.

Authors:  J M van Woerkom; A A Kruize; R Geenen; E N van Roon; R Goldschmeding; S M M Verstappen; J A G van Roon; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

2.  Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy.

Authors:  Harpreet Singh; Gagandeep Sukhija; Vikram Tanwar; Sameer Arora; Jaikrit Bhutani
Journal:  J Clin Diagn Res       Date:  2016-10-01

Review 3.  Leflunomide: friend or foe for systemic lupus erythematosus?

Authors:  Guo-Cui Wu; Xiao-Di Xu; Qiong Huang; Hua Wu
Journal:  Rheumatol Int       Date:  2012-09-08       Impact factor: 2.631

4.  Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy.

Authors:  Cemal Bes; Mehmet Soy
Journal:  Rheumatol Int       Date:  2009-10-21       Impact factor: 2.631

5.  Jessner-Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus?

Authors:  Laëtitia Sparsa; Naji Afif; Joëlle Goetz; Christelle Sordet; Emmanuel Chatelus; Dan Lipsker; Jean Sibilia
Journal:  Rheumatol Int       Date:  2009-10-13       Impact factor: 2.631

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.